Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake
PAR-19-360 R01, PAR-19-358 R21 and PAR-19-359 R03

Q&A

Research

The FOA indicates that it will not support research projects that rely solely on “patient/provider communication exclusively”. What does this mean exactly? Specifically, if one were to propose a trial that compared different methods of disseminating a provider/patient communication intervention that has a strong evidence base would this be of interest?
We are not interested in applications that exclusively address the patient/provider dyad. The focus of the announcement is on the characteristics at all three levels – clinic, parent/patient, provider – that affect uptake of HPV vaccination.

Will an intervention at alternate provider setting (such as dental office) will be eligible to apply for this program?
Appropriate sites for the intervention are those in which the recommendation and vaccine will be given in the same setting. These can include pharmacy and dental settings, if both criteria are met.

Any preference for survey type research versus intervention trials?
No preference. The method and approach should answer the research question of interest. Note the description in the announcement for a preference for mixed methods.

Research Setting

Was it stated that alternate settings where vaccine is not given cannot be eligible? For example, dentist can recommend but not give vaccine so dental setting are not appropriate for this RFA?
Correct. Appropriate sites for the intervention are those in which the recommendation and vaccine will be given in the same setting.

How about community clinics that are co-located with dental offices? Where the dentists would not be providing the vaccine but could recommend and refer to the clinic?
If the recommendation and vaccine could be given in the same location, the setting meets the requirement of the FOA.

Scientific Merit Review

Given there is no longer a special review group, do you have suggested study sections that might align with this PAR?
Finalize your aims and outcome measures before looking at study sections that could be a good match. Give consideration to Community Influences on Health Behavior (CIHB) Study Section and feel free to contact the Scientific Review Officer of this study section if you think the aims and outcome measures of your proposed study it aligns well with the description of the study section. Notes: feel free to provide descriptions of expertise needed to review your application to the SRO. Do NOT provide suggested reviewer names – these people will immediately be considered in conflict and not eligible.

If you can share... I’m curious why applications responding to this PAR will no longer be reviewed by a special emphasis panel?
The Center for Scientific Review approves separate review panels for FOA. Due to the high burden of running small panels, the request for a special emphasis panel for this FOA was not approved. Applicants
are welcomed to describe the expertise (do not mention names) needed to review their application in a cover letter that accompanies the submission of your SF424 application. Consideration will be given to your request to recruit and invite expertise requested to participate in the review of your application.

I am an early career investigator. With regards to R03 involving secondary analysis of existing data, an impediment that could occur is that a significant portion of the funding dollar will go into purchase of these data. Any advice on this?
Data should be related to the setting and population where the study will take place. Purchase of existing data sets may not be appropriate for research studies in response to this FOA.

**Key Dates**
Confirming the application due date. Is the R01 due March 5, 2020 and the R03 and R21 due February 16, 2020?

Due dates for the three funding mechanisms supported in the FOA are:

**R01**
The first standard due date for this FOA is February 5, June 5, and October 5 through September 08, 2022.

**R21**
Feb 15, June and October 16 through September 08, 2022.

**R03**
Feb 15, June and October 16 through September 08, 2022.